This article is a commentary on:
Postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement in patients with childhood-onset craniopharyngioma
Lukas Andereggen
Emanuel Christ- 1Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland
- 2Faculty of Medicine, University of Bern, Bern, Switzerland
- 3Department of Endocrinology, Diabetology and Metabolism, University Hospital of Basel, Basel, Switzerland
A Commentary on
Postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement in patients with childhood-onset craniopharyngioma
by Miao Y, Fan K, Peng X, Li S, Chen J, Bai RN, Wei Y, Deng Y, Zhao C, Wu Q, Ge M, Gong J and Wu D (2023) Front. Endocrinol. 14:1241145. doi: 10.3389/fendo.2023.1241145
We read with great interest the article by Miao et al. (1) reporting the long-term results of patients who underwent surgery for childhood-onset (CO) craniopharyngioma (CP). The number of patients included in the study is impressive, with 200 CP patients having CO. However, long-term follow-up data (median 29.7 months, range 19.0 to 40.3) was available for only about one third (71 patients, 36%), and among them, only 62 patients (31%) had documented regular visits at the endocrine department. The study recorded significant endocrinological sequelae post-surgery, with 94% of the 62 patients having undergone at least one form of hormone replacement therapy during the noted long-term follow-up. Miao et al. eloquently detailed the treatment plan for patients with endocrine dysfunction, emphasizing the crucial role of monitoring by an experienced pediatric endocrinologist. In addition to detailing the subsequent hormonal replacement therapy and the recorded tumor recurrence rate in 18 (26%) patients, it is crucial to incorporate long-term strategies into the adjuvant treatment plan in this patient cohort. Namely, in a comprehensive 10-year follow-up study of CP patients, we observed significant occurrences of hypothalamic obesity (HO) and enduring endocrine deficiencies (2). In addition to ongoing monitoring of endocrine deficiencies, it is imperative to implement early weight control programs and maintain continuous multidisciplinary care for this patient cohort (2).
As suffering from CP is currently a chronic, lifelong condition, the incorporation of long-term follow-up data as an outcome measure is essential to ensure and validate the therapy’s long-term safety and efficacy. It serves as a vital control mechanism for evaluating and adjusting the provided medical treatment (3). In particular, being a chronic disease (4), it highlights the necessity of conducting extended follow-up studies on the outcomes of surgical interventions to understand the sequelae experienced by individuals with CP over time. Namely, beside to the potential lifelong morbidity caused by the tendency of CP for local recurrence (5), it’s important to note risk factors that affect resection rates (i.e. prior radiation, tumor size) (6–8), recurrences (i.e. extent of resection, tumor size), and the quality of life (QoL, i.e. tumor size and entity, surgical approach, vision impairment, endocrine dysfunction, hypothalamic involvement) (9–12) during a longitudinal follow-up period. Regarding the likelihood of recurrence following transsphenoidal compared to transcranial approach, it would be intriguing to delve into more detailed information, such as the extent of tumor resection or the initial size of the tumor (1).
In terms of the specified hormonal replacement therapy, the use of recombinant growth hormone (rGH) therapy in CP patients has been found to be safe, with no reported association with the recurrence or progression of pituitary adenoma or benign tumors (13). Although traditionally a waiting period of at least one year for stable disease is recommended for malignant lesions, recent evidences suggest that this interval could be as short as three months for children with radiologically confirmed stable CP, especially those with significant growth failure and metabolic disturbances, as specified in the childhood cancer survivors (CCS) Consensus Statement (14). For children who have stable disease and concomitant GH deficiency, it is recommended to consider rGH therapy, which serves not only to improve adult height but also offers valuable metabolic benefits (15). Furthermore, it is cautioned against substituting ACTH deficiency with prednisolone in children due to the well-documented growth impairment associated with it (16). Additionally, the diagnosis of central hypothyroidism depends on low free thyroxine levels combined with inappropriately normal or low levels of thyroid-stimulating hormone (TSH), rather than relying solely on low TSH levels (17).
Traditionally, treatment strategies for CP have favored a radical approach involving gross-total resection, aiming to cure CP patients. We noted that none of the CPs recurred after gross total resection, compared to about one-fifth of patients following subtotal resection (2). However, evolving insights into risk-adapted therapy regimens have emerged over time, particularly for unfavorably located CP with hypothalamic involvement (HI) (18). The hypothalamic syndrome encompassing sleep-wake cycle disorders, temperature dysregulation, behavioral problems, and hypothalamic obesity (HO), poses significant challenges in the treatment strategy of CP patients (19). Namely, HO associated with impaired QoL are frequent and severe disabilities among CP patients (19). Therefore, strategies that spare the hypothalamus are highly recommended (2, 11, 20, 21), balancing radical resection for maximum safety with adjuvant treatment to control the disease in pediatric CP cases (22). Consequently, outcome parameters such as assessing HO are of paramount importance. Miao et al. (1) observed obesity in 54% of patients with recorded follow-up, while at baseline, it was noted in 76 out of 200 patients (38%). It can be assumed that weight gain was a substantial issue in this patient cohort. However, in CO cases, age-specific changes in weight gain and metabolic parameters should also be considered (23, 24), as they have been reported to significantly change during long-term follow-ups (2).
Regarding the comprehensive assessment of hypothalamic-pituitary dysfunction, evaluating treatment-related lesions of the optic apparatus and endocrine deficiencies only partially captures the therapeutic challenges in CP patients. This condition, especially in CO cases, is a chronic, incurable disease with anticipated lifelong effects, necessitating ongoing and multidisciplinary care for proper management of clinical and neuropsychological sequelae post-surgery. The assertion by the authors that ensuring adequate pituitary hormone replacement therapy and increasing engagement in sports activities are effective in managing postoperative obesity (25) is an overstatement. Namely, regarding the treatment of HO in CO CP patients, the results are ambiguous. While pharmacotherapies (26, 27) and bariatric procedures (28) demonstrate varying efficacy (29), none have been proven effective in randomized controlled trials (30). Thus, the impact of HO on quality of life and neuropsychological health, including social functioning during education and independent living, is considerable for long-term survivors (11, 31, 32). Therefore, it is advisable to prevent HO throughout hypothalamus-sparing surgical and radio-oncological strategies (21).
In summary, the treatment strategies for CO CP patients involve various complexities. Long-term follow-up studies are crucial to validate therapy effectiveness and ensure safety in managing this chronic disease. Strategies sparing the hypothalamus are advised to balance radical resection with the need for effective disease control. The impact of HO on patients’ quality of life is substantial, necessitating ongoing multidisciplinary care post-surgery. However, treatments for HO, such as pharmacotherapies and bariatric procedures, exhibit diverse effectiveness, emphasizing the need for further exploration in improving the well-being of long-term CP survivors.
Author contributions
LA: Conceptualization, Writing – original draft, Writing – review & editing. EC: Conceptualization, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article. No funding was received.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Miao Y, Fan K, Peng X, Li S, Chen J, Bai RN, et al. Postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement in patients with childhood-onset craniopharyngioma. Front Endocrinol (Lausanne). (2023) 14:1241145. doi: 10.3389/fendo.2023.1241145
2. Andereggen L, Hess B, Andres R, El-Koussy M, Mariani L, Raabe A, et al. A ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Weekly. (2018) 148:w14521. doi: 10.4414/smw.2018.14521
3. Norrie J. The importance of long-term follow-up in clinical trials. Lancet Glob Health. (2023) 11:e995–6. doi: 10.1016/S2214-109X(23)00244-9
4. Muller H. Craniopharyngioma - a chronic disease. Swiss Med Weekly. (2018) 148:w14548. doi: 10.4414/smw.2018.14548
5. Olsson DS, Buchfelder M, Wiendieck K, Kremenevskaja N, Bengtsson BA, Jakobsson KE, et al. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. Eur J endocrinology/European Fed Endocrine Societies. (2012) 166:1061–8. doi: 10.1530/EJE-12-0077
6. Yousuf OK, Salehani A, Zimmerman K, Estevez-Ordonez D, Madura C, Arynchyna-Smith A, et al. Does subtotal resection ameliorate hypothalamic morbidity in pediatric craniopharyngioma? A 30-year retrospective cohort study. J Neurosurg Pediatr. (2023) 32:569–75. doi: 10.3171/2023.5.PEDS22568
7. Bakhsheshian J, Jin DL, Chang KE, Strickland BA, Donoho DA, Cen S, et al. Risk factors associated with the surgical management of craniopharyngiomas in pediatric patients: analysis of 1961 patients from a national registry database. Neurosurg Focus. (2016) 41:E8. doi: 10.3171/2016.8.FOCUS16268
8. Elliott RE, Hsieh K, Hochm T, Belitskaya-Levy I, Wisoff J, Wisoff JH. Efficacy and safety of radical resection of primary and recurrent craniopharyngiomas in 86 children. J Neurosurg Pediatr. (2010) 5:30–48. doi: 10.3171/2009.7.PEDS09215
9. Aldave G, Okcu MF, Chintagumpala M, Ruggieri L, Minard CG, Malbari F, et al. Comparison of neurocognitive and quality-of-life outcomes in pediatric craniopharyngioma patients treated with partial resection and radiotherapy versus gross-total resection only. J Neurosurg Pediatr. (2023) 31:453–62. doi: 10.3171/2022.12.PEDS22367
10. Guo Y, Pei L, Li Y, Li C, Gui S, Ni M, et al. Characteristics and factors influencing hypothalamic pituitary dysfunction in patients with craniopharyngioma. Front Endocrinol (Lausanne). (2023) 14:1180591. doi: 10.3389/fendo.2023.1180591
11. Sowithayasakul P, Beckhaus J, Boekhoff S, Friedrich C, Calaminus G, Muller HL. Vision-related quality of life in patients with childhood-onset craniopharyngioma. Sci Rep. (2023) 13:19599. doi: 10.1038/s41598-023-46532-y
12. Giese H, Haenig B, Haenig A, Unterberg A, Zweckberger K. Neurological and neuropsychological outcome after resection of craniopharyngiomas. J Neurosurg. (2019) 132:1425–34. doi: 10.3171/2018.10.JNS181557
13. Losa M, Castellino L, Pagnano A, Rossini A, Mortini P, Lanzi R. Growth hormone therapy does not increase the risk of craniopharyngioma and nonfunctioning pituitary adenoma recurrence. J Clin Endocrinol Metab. (2020) 105. doi: 10.1210/clinem/dgaa089
14. Boguszewski MCS, Boguszewski CL, Chemaitilly W, Cohen LE, Gebauer J, Higham C, et al. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. Eur J Endocrinology/European Fed Endocrine Societies. (2022) 186:P35–52. doi: 10.1530/EJE-21-1186
15. Boguszewski MCS, Cardoso-Demartini AA, Boguszewski CL, Chemaitilly W, Higham CE, Johannsson G, et al. Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice. Pituitary. (2021) 24:810–27. doi: 10.1007/s11102-021-01173-0
16. Punthakee Z, Legault L, Polychronakos C. Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency. J Pediatr. (2003) 143:402–5. doi: 10.1067/S0022-3476(03)00294-4
17. Beck-Peccoz P, Rodari G, Giavoli C, Lania A. Central hypothyroidism - a neglected thyroid disorder. Nat Rev Endocrinol. (2017) 13:588–98. doi: 10.1038/nrendo.2017.47
18. Daubenbuchel AM, Hoffmann A, Gebhardt U, Warmuth-Metz M, Sterkenburg AS, Muller HL. Hydrocephalus and hypothalamic involvement in pediatric patients with craniopharyngioma or cysts of Rathke’s pouch: impact on long-term prognosis. Eur J Endocrinology/European Fed Endocrine Societies. (2015) 172:561–9. doi: 10.1530/EJE-14-1029
19. Sterkenburg AS, Hoffmann A, Gebhardt U, Warmuth-Metz M, Daubenbuchel AM, Muller HL. Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. Neuro Oncol. (2015) 17:1029–38. doi: 10.1093/neuonc/nov044
20. Muller HL. Craniopharyngioma and hypothalamic injury: latest insights into consequent eating disorders and obesity. Curr Opin Endocrinol Diabetes Obes. (2016) 23:81–9. doi: 10.1097/MED.0000000000000214
21. Bogusz A, Boekhoff S, Warmuth-Metz M, Calaminus G, Eveslage M, Muller HL. Posterior hypothalamus-sparing surgery improves outcome after childhood craniopharyngioma. Endocr Connect. (2019) 8:481–92. doi: 10.1530/EC-19-0074
22. Caklili M, Uzuner A, Yilmaz E, Duman Ozturk S, Cizmecioglu Jones FM, Balci S, et al. Surgical outcomes and follow-up results of 53 pediatric craniopharyngioma cases: a single-center study. J Neurosurg Pediatr. (2023), 1–13. doi: 10.3171/2023.10.PEDS23293
23. Hayes A, Gearon E, Backholer K, Bauman A, Peeters A. Age-specific changes in BMI and BMI distribution among Australian adults using cross-sectional surveys from 1980 to 2008. Int J Obes (Lond). (2015) 39:1209–16. doi: 10.1038/ijo.2015.50
24. Feng L, Nian S, Tong Z, Zhu Y, Li Y, Zhang C, et al. Age-related trends in lipid levels: a large-scale cross-sectional study of the general Chinese population. BMJ Open. (2020) 10:e034226. doi: 10.1136/bmjopen-2019-034226
25. Holmer H, Pozarek G, Wirfalt E, Popovic V, Ekman B, Bjork J, et al. Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma. J Clin Endocrinol Metab. (2010) 95:5395–402. doi: 10.1210/jc.2010-0993
26. Muller HL, Merchant TE, Puget S, Martinez-Barbera JP. New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat Rev Endocrinol. (2017) 13:299–312. doi: 10.1038/nrendo.2016.217
27. Roth CL, Zenno A. Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon. Front Endocrinol (Lausanne). (2023) 14:1256514. doi: 10.3389/fendo.2023.1256514
28. van Santen SS, Wolf P, Kremenevski N, Boguszewski CL, Beiglbock H, Fiocco M, et al. Bariatric surgery for hypothalamic obesity in craniopharyngioma patients: A retrospective, matched case-control study. J Clin Endocrinol Metab. (2021) 106:e4734–45. doi: 10.1210/clinem/dgab518
29. Dimitri P. Treatment of acquired hypothalamic obesity: now and the future. Front Endocrinol (Lausanne). (2022) 13:846880. doi: 10.3389/fendo.2022.846880
30. Muller HL. Management of hypothalamic obesity. Endocrinol Metab Clin North Am. (2020) 49:533–52. doi: 10.1016/j.ecl.2020.05.009
31. van Santen SS, Olsson DS, Hammarstrand C, Wijnen M, Fiocco M, van den Heuvel-Eibrink MM, et al. Body composition and bone mineral density in craniopharyngioma patients: A longitudinal study over 10 years. J Clin Endocrinol Metab. (2020) 105. doi: 10.1530/endoabs.70.AEP201
32. Wijnen M, Olsson DS, van den Heuvel-Eibrink MM, Hammarstrand C, Janssen J, van der Lely AJ, et al. The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. Eur J Endocrinology/European Fed Endocrine Societies. (2018) 178:11–22. doi: 10.1530/EJE-17-0387
Keywords: craniopharyngioma, hormone replacement therapy, obesity, hypothalamic involvement, recurrence, neuropsychological health
Citation: Andereggen L and Christ E (2024) Commentary: Postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement in patients with childhood-onset craniopharyngioma. Front. Endocrinol. 15:1371424. doi: 10.3389/fendo.2024.1371424
Received: 16 January 2024; Accepted: 15 February 2024;
Published: 27 February 2024.
Edited by:
Elena Varlamov, Oregon Health and Science University, United StatesReviewed by:
Giulia Rodari, IRCCS Ca ‘Granda Foundation Maggiore Policlinico Hospital, ItalyCopyright © 2024 Andereggen and Christ. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lukas Andereggen, bHVrYXMuYW5kZXJlZ2dlbkBrc2EuY2g=